Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

标题
Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 15_suppl, Pages 108-108
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2018-09-05
DOI
10.1200/jco.2018.36.15_suppl.108

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started